Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

(P059) Trends in the Utilization of Radiotherapy in the Management of Renal Cell Carcinoma

April 30, 2015
Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1
Conference|Annual Meeting of the American Radium Society (ARS)

There has been a decrease in the use of radiotherapy for patients with localized RCC, although patients with more aggressive disease were more likely to receive radiation. Modern trials are needed to better identify the role of radiation in the management of these patients.

Talha Shaikh, MD, Elizabeth A. Handorf, PhD, Colin Murphy, MD, Alexander Kutikov, MD, Robert G. Uzzo, MD, Mark Hallman, MD, PhD, Eric M. Horwitz, Marc C. Smaldone, MD, MSHP; Fox Chase Cancer Center

PURPOSE: The role of radiotherapy in the management of renal cell carcinoma (RCC) has been limited due to the belief that these tumors are relatively radioresistant. More recently, retrospective series have demonstrated good local control in patients undergoing radiation. We examined the temporal trends and patterns of use of radiotherapy in patients with localized RCC.

MATERIALS AND METHODS: Patients diagnosed with RCC were identified using the National Cancer Data Base. Our primary objective was to describe the temporal trends in the utilization of radiotherapy. Our second objective was to identify patient and treatment factors associated with receipt of radiation. Data were analyzed using the chi-square and Cochran-Armitage tests for trend.

RESULTS: A total of 330,426 were diagnosed with RCC between 1998 and 2010, with 18,522 (5.6%) patients receiving radiotherapy. After excluding patients with metastatic disease, 280,208 patients were diagnosed with localized RCC, with 3,552 (1.3%) patients receiving radiation therapy to the primary site. Factors associated with receipt of radiation included age > 71 years, no surgery (P < .0001), chemotherapy use (P < .0001), higher stage (P < .0001), higher grade (P < .0001), positive nodes (P < .0001), and sarcomatoid histology (P < .0001). A total of 257,304 patients underwent surgical resection in this cohort. Of these patients, 2,265 (0.9%) received adjuvant radiation. Patients receiving adjuvant radiotherapy were more likely to receive chemotherapy (P < .0001), have a higher stage (P < .0001), have a higher grade (P < .0001), have positive nodes (P < .0001), and have sarcomatoid histology (P < .0001).

CONCLUSIONS: There has been a decrease in the use of radiotherapy for patients with localized RCC, although patients with more aggressive disease were more likely to receive radiation. Modern trials are needed to better identify the role of radiation in the management of these patients.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Related Content

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.

Tivozanib Shows Efficacy in Pretreated Metastatic RCC

Kyle Doherty
June 11th 2025
Article

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Gina Mauro
June 11th 2025
Article

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.


Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL

Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL

Gina Mauro
June 10th 2025
Article

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.

Related Content

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.

Tivozanib Shows Efficacy in Pretreated Metastatic RCC

Kyle Doherty
June 11th 2025
Article

There appeared to be no extra benefit with the addition of nivolumab to tivozanib among patients included in the phase 3 TiNivo-2 trial.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.

Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

Gina Mauro
June 11th 2025
Article

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.


Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL

Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL

Gina Mauro
June 10th 2025
Article

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.